New triple therapy shows promise for Tough-to-Treat lung cancer
NCT ID NCT04340882
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests a combination of three drugs (chemotherapy, anti-angiogenesis, and immunotherapy) in 30 adults with advanced non-small cell lung cancer that worsened after standard treatments. The goal is to see if this triple therapy is safe and works better than current options to control the cancer. Participants must have already tried platinum-based chemo and an immunotherapy drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL LUNG CELL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Grady Health System
Atlanta, Georgia, 30303, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New drug combo shows promise for tough cancers
- New drug combo aims to reboot immune system against lung cancer